TLDR
- Liquidia (LQDA) stock sank 57% on Wednesday after losing a patent case.
- A Delaware federal court ruled Liquidia’s Yutrepia infringes a United Therapeutics patent.
- United Therapeutics (UTHR) stock rose 12% on the news.
- Trading volume hit 22.95 million shares, nearly 19 times the average.
- Liquidia plans to appeal and ask the FDA to change Yutrepia’s label.
Liquidia (LQDA) stock dropped 57% in Wednesday’s regular session, closing at $30.26. The stock ticked up slightly after hours, rising 0.13% to $30.30.
The sharp drop followed a federal court ruling in Delaware. The judge found that Liquidia’s lung drug Yutrepia infringes on a key patent held by rival United Therapeutics (UTHR).
Two claims from United Therapeutics’ patent were ruled valid and infringed. Other asserted claims in the case were found invalid.
The patent covers methods of treating pulmonary hypertension with interstitial lung disease, known as PH-ILD. It specifically applies to inhaled treprostinil delivered through dry powder formulations, which is how Yutrepia works.
What the Ruling Means for Yutrepia
The court also denied Liquidia’s motion to strike evidence tied to United Therapeutics’ patent ownership. The judge said Liquidia had enough notice before trial and didn’t raise objections in time.
Liquidia said it cannot yet estimate how much this will cost the company financially. That depends on appeals and what happens next in court.
Possible remedies on the table range from removing the PH-ILD indication from Yutrepia’s label to tighter restrictions on the drug’s sale. United Therapeutics has asked the court for an injunction to limit Yutrepia’s availability.
Both companies need to submit proposed judgments to the court within a week. A final decision is expected around that time.
Liquidia CEO Roger Jeffs pushed back on the ruling. “We respectfully disagree with the Court’s decision regarding claims 1 and 14 and are fully prepared to pursue all available appellate options,” he said.
Jeffs added that Liquidia will file a supplement to Yutrepia’s FDA application. The goal is to remove the PH-ILD indication from the drug’s label entirely.
Yutrepia won approval in 2025 for two uses: pulmonary arterial hypertension and PH-ILD. The PH-ILD portion is now the part in legal jeopardy.
How Wall Street Is Reading It
Analysts were split on how damaging the ruling really is. Raymond James analyst Ryan Deschner called the denied evidence motion a bad sign for Liquidia’s broader case.
Leerink Partners framed it as a win for United Therapeutics, since the court confirmed Yutrepia infringes a valid patent. RBC Capital’s Lisa Walter said the ruling clouds the path forward for Yutrepia competing in the market.
United Therapeutics stock jumped 12% to $540.54 following the decision. The ruling reinforces protection around its own blockbuster inhaled treatment, Tyvaso.
Liquidia’s stock hit its lowest point in nearly four months on the news. If losses hold, the company stands to lose roughly $3.18 billion in market value.
Trading activity spiked heavily around the news. Volume reached 22.95 million shares, close to 19 times the stock’s average of 1.21 million.
Liquidia’s Relative Strength Index sits at 20.23, a level typically considered oversold. The stock is now trading near just 12% of its 52-week range.
Despite Wednesday’s drop, Liquidia stock is still up 33% over the past 12 months. Its market cap stands at $2.71 billion, down from a 52-week high of $93.61 per share.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
